# US 8,772,225 B2 · Biomarkers for multiple sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,225 B2
- Document ID: US8772225B2
- Status: Granted
- Kind: B2
- Application number: 12/595,597
- Filed: 2008-04-14
- Published: 2010-11-25
- Granted: 2014-07-08
- Earliest claimed: 2007-04-12
- Assignees: Universiteit Hasselt
- Applicants: Veerle Somers; Pieter Stinissen
- Inventors: Veerle Somers; Pieter Stinissen
- Web page: https://patentgrep.com/patent/US8772225B2

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to the diagnosis of neurological disorders, more specifically to the diagnosis of multiple sclerosis. A biomarker panel is provided which can be used to detect if a subject has multiple sclerosis. Also described are methods of identification of such biomarkers.

## Claims

### Claim 1

A composition comprising at least two different polypeptides, the composition comprising SEQ ID NOS:1 and 8.

### Claim 2 (depends on 1)

A method of detecting the presence and/or quantity of specific antibodies to at least one polypeptide comprising a sequence represented by SEQ ID NO:1 and/or SEQ ID NO:8, the method comprising contacting cerebrospinal fluid of a mammal with the composition of claim 1, and detecting the presence and/or measuring the quantity of the specific antibodies bound to the composition.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the mammal is a human.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the detecting and/or measuring comprises utilizing an immune-enzymatic process selected from the group consisting of an enzyme-linked immunosorbant assay (ELISA), an immunofluorescent technique, a radioimmunological assay (RIA), immunoblotting and a LINE blot.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the presence and/or quantity of at least one specific antibody is indicative for multiple sclerosis.

### Claim 6 (depends on 1)

A diagnostic kit for the detection of multiple sclerosis, the diagnostic kit comprising the composition of claim 1, reagents for making a medium appropriate for an immunological reaction to occur, and reagents enabling detection of the antigen/antibody complex, which has been produced by the immunological reaction between antibodies from a cerebrospinal fluid of a human and the composition of claim 1.

### Claim 7 (depends on 1)

The composition of claim 1, wherein one or more of the polypeptides are bound to a solid support.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the composition forms part of an ELISA.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the polypeptides are labeled.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the label comprises an enzymatic, fluorescent, biotin, or radioactive label.